Steering Committee

Florence Dal Degan is Senior Director, External Innovation, at Ipsen. In her role, she is responsible for the identification and evaluation of innovative external opportunities from discovery to late clinical stage within rare diseases and neuroscience. Florence has 10 years’ international experience in external innovation and business development and 20 years’ experience in R&D, where she has held various scientific and leadership positions at Novo Nordisk, Zealand Pharma and Pharmexa. Florence holds a Ph.D. in protein biology.

Corinne has garnered deep expertise in R&D and Project management along with Strategic Alliances identification and Business Development in the health sector. She has more than 25 years’ experience in pharma – mainly at Pfizer – and biotech, at operational and strategic levels and more than 10 years in strategical consulting in healthcare and more largely in the biotech sector. Her area of expertise includes drug candidate development (NCEs and biologics), cell and gene therapy, biomarkers, nutraceuticals and bioprocesses.  She has also strong experience in change management, R&D processes harmonization, leadership of integration programs following M&A operations and leading matrix structures.

Corinne holds a PhD in Biochemistry from the University of Sherbrooke, Canada, a MSc in Human Physiopathology from the University Paul Sabatier, Toulouse, France and an Executive MBA from the French business school HEC Paris, France. She also completed training with the French Navy on the Management and Leadership in Crisis Situations.

Sara is co-Founder and Partner at Forty51 Ventures, an emerging Biotech venture fund focused on venture formation. Previously, Sara Núñez-García served as Partner and Head of European Investments at Roivant Sciences where she led investments across several therapeutic areas in the Biotech space. Prior, Sara served as Principal with Sofinnova Partners. She invested in Delinia Bio (acquired by Celgene), ProQR Therapeutics [PRQR], Auris Medical [EARS], MedDay Pharma, ObsEva [OBSV], Enyo Pharma, Asceneuron, MyTomorrows, Leucid Bio and Comet Therapeutics. She served on the Board in several portfolio companies.

Sara spent seven years in the Pharma industry in a preclinical development role and was also an Associate in the Licensing and M&A team at Onyx Pharmaceuticals (now Amgen) in California.

In addition, Sara did her postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed several inhibitors for oncology targets, one of which was in-licensed by Biocryst and is currently in clinical development. Sara received her PhD in Chemistry from the University of Manchester, UK. In addition, Sara holds an MBA from INSEAD with a major in Finance.

Daniel joined the TVM Capital Life Science team as Executive-in-Residence based in Munich in September 2016.

He is responsible for deal sourcing, deal monitoring as well as transaction advisory. He is and was a member of the Board of Directors at leon-nanodrugs GmbH, Munich, Centogene AG, Rostock, MicrobeDx, Inc. Los Angeles, CA, Prothea-X Ltd, Edinburgh and is an observer to the Board of Directors at Mediti Pharma, Inc. Montreal, QC.

Daniel joined TVM from Novartis AG, where he spent 12 years in three Divisions including Pharma in Basel, Switzerland, Vaccines & Diagnostics in Emeryville, CA, USA and Sandoz (Generics / Biopharmaceuticals) in Holzkirchen / Munich, Germany. He held various line function across the three Businesses including Global Franchise Head Strategic Marketing for Immunology & Infectious Diseases in Pharma and Global Head of Development, Diagnostics. He oversaw and was a team member for multiple collaborations, licensing deals and acquisitions from academic to multi-billion dollar transactions, world-wide commercial launches and FDA / EMA / CFDA / ANVISA registrations with respective clinical trials.

Prior to Novartis he was at McKinsey & Company, Inc. and was trained as an MD at Johannes-Gutenberg-University Mainz, Germany with clinical training in Germany, Switzerland and the USA (UC Davis Medical Center, Sacramento, CA) and having been a scientific co-worker at the Institute for Occupational, Social and Environmental Medicine in Mainz for several years.

Biography available soon!

Jérôme MAJOIE is the General Manager of the Foundation Fournier-Majoie, a Venture philanthropic foundation dedicated to recognize and support innovative and entrepreneurial researchers or teams, willing to develop biomolecular applications leading to improvements of diagnostics and treatments in oncology to the benefit of cancer patients. He has 14 years’ experience in the pharmaceutical industry at Lipha-Merck, Pfizer and Fournier Group in Sales Marketing, Business Development and Licensing departments. Jerome has lived and worked in the USA, the UK, Sweden, Japan as General Manager. Since 2005, he is coaching start-up companies in the biotech industry. Jerome holds an MBA from Hartford University (CT, USA).  

Dr Frank Hensel holds a PH.D. in biology and has a longstanding experience as Entrepreneur in a Start-Up developing human monoclonal antibodies for cancer treatment. Since being part of HTGF in 2015 Frank built a solid portfolio of start-ups with a focus on drug development companies. Out of this portfolio 3 companies already entered the clinical stage and one company, Amal therapeutics, was successfully exited to Boehringer Ingelheim with a deal volume of up to 425Mio. €

Industrial Pharmacist Degree

Graduated in Biostatistics

Master’s Degree in Business Administration

25 years of experience as Sales and Marketing Director in Medical Devices and In Vitro Diagnostics

9 ½ years of experience as Business Developer in Medical Devices and In Vitro Diagnostics at SATT Nord

Business Unit Manager Healthcare at SATT Nord

Alain Martelli is a molecular and cellular biologist by training, with a PhD in Bioorganic Chemistry from the University of Grenoble, France. Alain worked for more than 15 years in academic research, where he developed a strong expertise in molecular biology, iron metabolism and rare disease, specifically in the rare neuromuscular disorder Friedreich ataxia. In 2016, Alain joined the Pfizer Rare Disease Research Unit in Cambridge (MA), USA, where he led several early-stage programs and collaborations involving both gene therapy and small molecule approaches. In 2022, Alain moved back to France to join a small biotech company, Innoskel, as Senior Director of Translational Medicine, to oversee the translational development of a novel gene therapy for a rare bone disorder. In July 2023, Alain was hired back by Pfizer as Emerging Science Lead to help build strong collaborations between Pfizer and the French academic research and biotech ecosystems.

Chloé is Global R&D Search and Evaluation Director at Servier, in charge of the scouting for external innovation to nurture the pipeline and research platforms. She has > 15 years experience in life sciences business development sector and joined Servier’s Global Business Development Team in 2018 to lead partnering deals in the Discovery and early development space. Before joining Servier, Chloé worked at Onxeo, a listed biotech company in Paris, where she was Program Acquisition Manager, involved in all aspects of scouting, due diligence and deal-making. She has a technology transfer background having previously worked for many years at France Innovation Scientifique et Transfert (FIST), CNRS’ TTO, where she was in charge of the protection, valuation and licensing of the inventions coming from the CNRS labs, in the field of neurology and rare diseases.

Chloé is a scientist by training, holding a PhD in aging biology from Université Paris Cité, as well as an MBA from IAE Paris Sorbonne Business School.

Dr. Stephan Lensky joined EpimAb early on and is responsible for EpimAb’s strategy and business development, bring in more than 15 years of business development experience with multi-national pharmaceutical companies.  Previously he headed the Corporate Department for Strategic Transactions & Alliance Management at Boehringer Ingelheim GmbH, responsible for the negotiation and management of all strategic transactions of Prescription Medicines (PM) Business.  Prior to that, he led a group at Bayer responsible for all commercial licenses in Europe and the Emerging Markets. Dr. Lensky holds a Ph.D. in Chemistry, and is a member of the BioFIT Steering Committee since 2014.

Eva Dahlén, Ph.D., is Director, Search & Evaluation, at Novo Nordisk. In this capacity, she leads innovation sourcing activities across a range of technology areas, including RNA & gene therapy, oral and alternative delivery of biologics, and AI/ML-enabled target and drug discovery, applicable in cardiometabolic and rare diseases. With > 20 years experience in the life science sector, Eva has held various positions in BD and R&D, most recently as senior director business development at Alligator Bioscience, and prior roles including principal scientist and project and team leader positions for discovery and development of immunotherapeutic drugs.

Eva has a scientific background in immunology and oncology. She holds a Ph.D. in immunology from Lund university, Sweden, and has conducted research in basic immunology, inflammation and immuno-oncology.

Master in Business Engineering
(Solvay Business School ULB)
Consultant for technology focused SME
(including MBO participation)
Consulting / Senior Management for large corporations in Belgium and Europe
CFO (part-time) from 2001 to 2012 of Delphi Genetics and CBO (Chief Business Officer) from 2012 to May 2014